Zebrafish live imaging: a strong weapon in anticancer drug discovery and development

被引:2
作者
Zhan, Tiancheng [1 ,2 ]
Song, Wanqian [1 ,2 ]
Jing, Guo [1 ,2 ]
Yuan, Yongkang [1 ]
Kang, Ning [1 ]
Zhang, Qiang [1 ]
机构
[1] Tianjin Univ Tradit Chinese Med, Sch Med Technol, 10 Poyanghu Rd, Tianjin 301617, Peoples R China
[2] Tianjin Univ Tradit Chinese Med, Sch Integrat Med, Tianjin, Peoples R China
基金
中国国家自然科学基金;
关键词
Cancer; Zebrafish; Live imaging; Drug screening; ADULT ZEBRAFISH; TUMOR-GROWTH; HUMAN CANCER; CELL; MODEL; TOXICITY; ANGIOGENESIS; METASTASIS; INHIBITOR; XENOGRAFT;
D O I
10.1007/s12094-024-03406-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Developing anticancer drugs is a complex and time-consuming process. The inability of current laboratory models to reflect important aspects of the tumor in vivo limits anticancer medication research. Zebrafish is a rapid, semi-automated in vivo screening platform that enables the use of non-invasive imaging methods to monitor morphology, survival, developmental status, response to drugs, locomotion, or other behaviors. Zebrafish models are widely used in drug discovery and development for anticancer drugs, especially in conjunction with live imaging techniques. Herein, we concentrated on the use of zebrafish live imaging in anticancer therapeutic research, including drug screening, efficacy assessment, toxicity assessment, and mechanism studies. Zebrafish live imaging techniques have been used in numerous studies, but this is the first time that these techniques have been comprehensively summarized and compared side by side. Finally, we discuss the hypothesis of Zebrafish Composite Model, which may provide future directions for zebrafish imaging in the field of cancer research.
引用
收藏
页码:1807 / 1835
页数:29
相关论文
共 50 条
  • [1] Live imaging in zebrafish reveals neu(trophil) insight into the metastatic niche
    Patton, E. Elizabeth
    JOURNAL OF PATHOLOGY, 2012, 227 (04) : 381 - 384
  • [2] What value do zebrafish have to anticancer drug discovery?
    Xiao, Boyuan
    Landesman-Bollag, Esther
    Feng, Hui
    EXPERT OPINION ON DRUG DISCOVERY, 2024, 19 (04) : 369 - 375
  • [3] Zebrafish as an emerging tool for drug discovery and development for thyroid diseases
    Yadav, Poonam
    Sarode, Lopmudra P.
    Gaddam, Ravinder Reddy
    Kumar, Puneet
    Bhatti, Jasvinder Singh
    Khurana, Amit
    Navik, Umashanker
    FISH & SHELLFISH IMMUNOLOGY, 2022, 130 : 53 - 60
  • [4] Bioluminescent zebrafish transplantation model for drug discovery
    Hason, Martina
    Jovicic, Jovana
    Vonkova, Ivana
    Bojic, Milan
    Simon-Vermot, Theresa
    White, Richard M.
    Bartunek, Petr
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [5] Zebrafish Xenografts for Drug Discovery and Personalized Medicine
    Xiao, Jerry
    Glasgow, Eric
    Agarwal, Seema
    TRENDS IN CANCER, 2020, 6 (07): : 569 - 579
  • [6] Zebrafish xenograft models of cancer and metastasis for drug discovery
    Brown, Hannah K.
    Schiavone, Kristina
    Tazzyman, Simon
    Heymann, Dominique
    Chico, Timothy J. A.
    EXPERT OPINION ON DRUG DISCOVERY, 2017, 12 (04) : 379 - 389
  • [7] Zebrafish for modeling stroke and their applicability for drug discovery and development
    Crilly, Siobhan
    McMahon, Emily
    Kasher, Paul R.
    EXPERT OPINION ON DRUG DISCOVERY, 2022, 17 (06) : 559 - 568
  • [8] Strategies for the drug discovery and development of taxane anticancer therapeutics
    Wang, Changwei
    Aguilar, Angelo
    Ojima, Iwao
    EXPERT OPINION ON DRUG DISCOVERY, 2022, 17 (11) : 1193 - 1207
  • [9] Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs
    Shim, Joong Sup
    Liu, Jun O.
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2014, 10 (07): : 654 - 663
  • [10] Zebrafish Patient-Derived Xenograft Model as a Preclinical Platform for Uveal Melanoma Drug Discovery
    Yin, Jie
    Zhao, Gangyin
    Kalirai, Helen
    Coupland, Sarah E.
    Jochemsen, Aart G.
    Forn-Cuni, Gabriel
    Wierenga, Annemijn P. A.
    Jager, Martine J.
    Snaar-Jagalska, B. Ewa
    Groenewoud, Arwin
    PHARMACEUTICALS, 2023, 16 (04)